

UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address:

COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.
09/125,114	08/18/98	PRICE	I	P8129-8004

HM22/0303

NIKAIDO MARMELSTEIN MURRAY & ORAM METROPOLITAN SQUARE 655 FIFTEENTH STREET NW SUITE 330 G STREET LOBBY WASHINGTON DC 20005-5701

EXAMINER				
BERMAN, A				
ART UNIT	PAPER NUMBER			

Please find below and/or attached an Office communication concerning this application or

DATE MAILED:

Commissioner of Patents and Trademarks

proceeding.

Office Action Summary

Application No. 09/125,114

Applicant(s)

Price, lan Ashley

Examiner

Alysia Berman

Group Art Unit 1615

Responsive to communication(s) filed on	
☐ This action is FINAL .	
☐ Since this application is in condition for allowance except for in accordance with the practice under <i>Ex parte Quayle</i> , 1935	formal matters, prosecution as to the merits is closed in C.D. 11; 453 O.G. 213.
A shortened statutory period for response to this action is set to is longer, from the mailing date of this communication. Failure t application to become abandoned. (35 U.S.C. § 133). Extensio 37 CFR 1.136(a).	to respond within the period for response will cause the
Disposition of Claims	
	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
☐ Claims	
Application Papers	
☐ See the attached Notice of Draftsperson's Patent Drawing	Review, PTO-948.
☐ The drawing(s) filed on is/are objecte	ed to by the Examiner.
☐ The proposed drawing correction, filed on	isapproveddisapproved.
🛚 The specification is objected to by the Examiner.	
$\hfill\Box$ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	
Acknowledgement is made of a claim for foreign priority u	nder 35 U.S.C. § 119(a)-(d).
	the priority documents have been
🔀 received.	
received in Application No. (Series Code/Serial Numl	
☐ received in this national stage application from the Ir	nternational Bureau (PCT Rule 17.2(a)).
*Certified copies not received:	
☐ Acknowledgement is made of a claim for domestic priority	under 35 U.S.C. § 119(e).
Attachment(s)	
Notice of References Cited, PTO-892 Notice of References Cited, PTO-4440, Process No. 1	(-)
☐ Information Disclosure Statement(s), PTO-1449, Paper No(☐ Interview Summary, PTO-413	,S)
☐ Notice of Draftsperson's Patent Drawing Review, PTO-948	}
□ Notice of Informal Patent Application, PTO-152	,
••	
·	
SEE OFFICE ACTION ON TH	IE FOLLOWING PAGES

DETAILED ACTION

Receipt is acknowledged of Preliminary Amendment A filed on 18 August 1998. Claims 1-7, 10, 16-18, and 21-26 are allowed.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 8, 9, 11-15 and 20 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 8 and 9 are indefinite because they are claiming Markush groups but are not written in proper Markush form. The proper format of a Markush claim is, "selected from the group consisting of A, B and C." Correction is required. See MPEP § 2173.05(h).

Claims 11-15 provide for the use of an alkali metal carbonate or bicarbonate, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claims 11-15 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for

Application/Control Number: 09/125114

Price

Art Unit: 1615

Page 3

example Ex parte Dunki, 153 USPQ 678 (Bd.App. 1967) and Clinical Products, Ltd. v. Brenner, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

The term "substantially dry" in claim 20 is a relative term which renders the claim indefinite. The term "substantially dry" is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Since "substantially dry" is not defined in the specification, it is unclear to what degree the mixture must be dry to meet the limitation.

Removal of the phrase "substantially dry" is required.

Claim Objections

Claims 13, 14, and 19 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. As to claim 13, it is dependent on a subsequent claim. As to claims 14 and 19, they are dependent on themselves and, therefore, do not further limit any previous claim. Dependent claims must be dependent on a previous claim and add a further limitation to the previous claim that is depends from.

Specification

This application does not contain an abstract of the disclosure as required by 37 CFR 1.72(b). An abstract on a separate sheet is required.

A substitute specification excluding claims is required pursuant to 37 CFR 1.125(a) because it is not arranged properly and much of the typing is barely legible.

A substitute specification filed under 37 CFR 1.125(a) must only contain subject matter from the original specification and any previously entered amendment under 37 CFR 1.121. If the substitute specification contains additional subject matter not of record, the substitute specification must be filed under 37 CFR 1.125(b) and must be accompanied by: 1) a statement that the substitute specification contains no new matter; and 2) a marked-up copy showing the amendments to be made via the substitute specification relative to the specification at the time the substitute specification is filed.

The following guidelines illustrate the preferred layout and content for patent applications.

These guidelines are suggested for the applicant's use.

Arrangement of the Specification

The following order or arrangement is preferred in framing the specification and, except for the reference to "Microfiche Appendix" and the drawings, each of the lettered items should appear in upper case, without underlining or bold type, as section headings. If no text follows the section heading, the phrase "Not Applicable" should follow the section heading:

Application/Control Number: 09/125114

Price

Art Unit: 1615

- (a) Title of the Invention.
- (b) Cross-References to Related Applications.
- (c) Statement Regarding Federally Sponsored Research or Development.
- (d) Reference to a "Microfiche Appendix" (see 37 CFR 1.96).
- (e) Background of the Invention.
 - 1. Field of the Invention.
 - 2. Description of the Related Art including information disclosed under 37 CFR 1.97 and 1.98.
- (f) Brief Summary of the Invention.
- (g) Brief Description of the Several Views of the Drawing(s).
- (h) Detailed Description of the Invention.
- (i) Claim or Claims (commencing on a separate sheet).
- (j) Abstract of the Disclosure (commencing on a separate sheet).
- (k) Drawings.
- (l) Sequence Listing (see 37 CFR 1.821-1.825).

Drawings

Acknowledgment is made of informal drawings submitted with the original specification.

The specification does not contain a brief description of the drawings as required by 37 CFR 1.74.

Submission of a brief description of the drawings is required with the substitute specification. See § MPEP 608.01(f).

Allowable Subject Matter

Claims 8, 9, 11-15 and 20 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112, 2nd paragraph, set forth in this Office action.

Page 5

Price

Art Unit: 1615

As allowable subject matter has been indicated, applicant's reply must either comply with all formal requirements or specifically traverse each requirement not complied with. See 37 CFR 1.111(b) and MPEP § 707.07(a).

Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Gregory et al. (US 5262179) discloses a non-effervescent sodium salt ibuprofen composition in the form of a powder that my be made into a tablet. However, Gregory does not teach the larger doses of ibuprofen, the crushing strength or the disintegration time of the powder. Geisslinger et al. (US 5565613) discloses a formulation for the calcium salt of ibuprofen optionally in combination with the sodium salt of ibuprofen formed into a tablet by direct dry compressed. Geisslinger does not teach the use of the sodium salt of ibuprofen alone

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alysia Berman whose telephone number is (703) 308-4638. The examiner can normally be reached on Monday-Friday from 8:30 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page, can be reached on (703) 308-2927. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Application/Control Number: 09/125114

Price

Art Unit: 1615

Page 7

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1234 or 1235.

TUURWAY N. PAGE
SUPERVISORY PATENT EXAMINER
ART UNIT 152 161

Alysia Berman Patent Examiner February 23, 1999